Journal of Affective Disorders
July 15, 2026
Iman Kiani, Giulia Cattarinussi, Fabio Sambataro et al.
Major depressive disorder (MDD) is a leading cause of disability worldwide, with a significant portion of patients experiencing treatment-resistant depression (TRD). Ketamine, a rapid-acting antidepressant, has shown promise in alleviating symptoms of TRD and suicidality, but variability in treatment response remains a challenge. Identifying neuroimaging biomarkers that predict responsiveness...
Frontiers in Systems Neuroscience
June 4, 2026
Elena Bondi, Flavia Carbone, Giandomenico Schiena et al.
Introduction: Affective disorders (ADs) are characterized by profound emotional processing deficits involving disrupted neural network activity and connectivity, particularly within the default mode network and fronto-temporal circuits, with abnormalities in theta and alpha oscillatory patterns. While current treatments primarily target mood symptoms, emotional processing impairments often...
Frontiers in Psychiatry
2026
Giovanni Videtta, Elena Bondi, Chiara Colli et al.
The Assessment of Clinician's Subjective Experience (ACSE) is a self-report questionnaire developed to evaluate clinicians' subjective experiences during patient interactions. While its psychometric properties and clinical validity have been supported, its neurobiological correlates have not yet been investigated. In this pilot study, two clinicians and ten patients participated in a...
Journal of Affective Disorders
February 1, 2025
Farzaneh Ramezani, Peyman Mardani, Fatemeh Nemati et al.
4 citations
Over the last two decades, ketamine has gained significant interest in psychiatry as a potential treatment for major depressive disorder (MDD), especially in individuals who are resistant to traditional therapies or are at a high risk of suicide. Task-based functional magnetic resonance imaging (fMRI) studies can provide insight into how ketamine alters brain function and contributes to its...
Journal of Visualized Experiments
August 18, 2020
Giuseppe Delvecchio, Lucio Oldani, Gian Mario Mandolini et al.
3 citations
Cannabis is the illicit drug most commonly used worldwide, and its consumption can both induce psychiatric symptoms in otherwise healthy subjects and unmask a florid psychotic picture in patients with a prior psychotic risk. Previous studies suggest that chronic and long-term cannabis exposure may exert significant negative effects in brain areas enriched with cannabinoid receptors. However,...